Claudia Zuany-Amorim

TL;DR: Treatment of mice with SRP299, a killed Mycobacterium vaccae-suspension gives rise to allergen-specific CD4+CD45RBLo regulatory T cells, which confer protection against airway inflammation and may have an essential role in restoring the balance of the immune system to prevent and treat allergic diseases.

TL;DR: The current and future use of TLR agonists or antagonists in chronic inflammatory diseases are discussed and potential problems that are associated with such approaches are highlighted.

TL;DR: The inhibitory effect of FTY720 on airway inflammation, induction of bronchial hyperresponsiveness, and goblet cell hyperplasia could be confirmed in an actively Ag-sensitized murine asthma model, clearly indicating that Th2 cell-driven allergic diseases such as asthma could benefit from such treatment.

TL;DR: Results clearly demonstrate that M. vaccae is effective in blocking allergic inflammation by a mechanism independent of IFN-γ, induces long term and Ag-specific protection, and therefore has both prophylactic and therapeutic potential for the treatment of allergic diseases.

TL;DR: The induction of anti-TNF- α autoantibody production by the AutoVac TNF106 technology not only confirmed the role of TNF-α in the induction of allergic inflammation but also offers a novel approach to block the activity of cytokines in order to treat allergic inflammatory conditions.